NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial

· Issued by NewAmsterdam Pharma Company N.V.

-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer’s disease biomarker in both the full ITT population (p

NewAmsterdam Pharma Company N.V. on 6ix

In the deck

Story so far

Earlier from NewAmsterdam Pharma

Later from NewAmsterdam Pharma

All NewAmsterdam Pharma news releases